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adherence/persistence and eight were able to improve the blood glucose levels of 
patients (double counting in three cases); ﬁ ve had no effect at all. Four dimensions of 
the methodological quality of AI programs were identiﬁ ed: 1) measurement of adher-
ence/persistence/clinical outcomes, 2) measurement of NA/NP causes, 3) use of effec-
tive/validated intervention measures; and 4) effective program evaluation. The authors 
deﬁ ned 5 detailed methodological requirements per dimension and, based on this, 
developed a corresponding scoring model (MIN Score 0, MAX score 20). All 19 AI 
programs were evaluated in the scoring model (average score 8.05): • Score <5: 3 
AI—no adherence/blood glucose level improvement; • Score 5–9: 8 AI—6 with 
improvement in both adherence and/or blood glucose levels; • Score >9: 8 AI—all 
improved adherence and/or blood glucose levels. CONCLUSIONS: The scoring model 
provides a starting point for the methodical evaluation of AI. However, further devel-
opment and testing of both the elements and construction is needed for medical indica-
tions other than diabetes type II.
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OBJECTIVES: To translate the MMAS into the Malaysian language, and to examine 
the psychometric properties of the Malaysian version of the MMAS among patients 
with type 2 diabetes, including its validity and reliability. METHODS: After obtaining 
permission, a standard “forward-backward” translation procedure was used to create 
the Malaysian version of the MMAS from the original English version. a convenience 
sample of 223 outpatients with type 2 diabetes was identiﬁ ed between May and Sep-
tember, 2009. All data were collected from the Penang General Hospital, Penang, 
Malaysia. Instruments consisted of the Malaysian version of MMAS, the Malaysian 
version of the old four-item Morisky scale and a sociodemographic questionnaire. 
Medical records were reviewed for hemoglobin A1C (HbA1C) levels and other clinical 
data. Reliability was tested for internal consistency using Cronbach’s α coefﬁ cient. 
Validity was conﬁ rmed using convergent and known group validity. RESULTS: 
Employing the recommended scoring method, the mean ± SD of MMAS scores was 
6.13 ± 1.72. Moderate internal consistency was found, (Cronbach’s α = 0.675), the 
test-retest reliability value by using Spearman’s rank correlation was 0.816 (P < 
0.001). a positive correlation between the eight- and four-item MMAS was found (r 
= 0.792; P < 0.01). For known group validity, a signiﬁ cant relationship between 
MMAS categories and HbA1c categories (χ2 = 20.261; P ≥ 0.001) was found. The 
MMAS sensitivity and speciﬁ city, with positive and negative predictive values were 
77.61%, 45.37%, 46.84% and 76.56%, respectively. CONCLUSIONS: The MMAS 
can be used for medication adherence measurement in diabetes. The ﬁ ndings of this 
validation study indicate that the Malaysian version of the MMAS is a reliable and 
valid measure of medication adherence which can now be used in clinical practice.
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OBJECTIVES: The last decade several studies have proven that lifestyle interventions 
can be effective for people with or at risk for diabetes. Because effectiveness of preven-
tive interventions is affected by non-participation (adherence), it is important to 
understand factors inﬂ uencing people’s willingness to participate in a lifestyle interven-
tion. Therefore, the aim of this exploratory analysis is to examine which factors of a 
lifestyle program inﬂ uence its valuation and willingness to participate. METHODS: 
We used conjoint analysis to empirically examine associations between the factors that 
inﬂ uence participation and participants’ valuation of an intervention and participants’ 
willingness to participate in a lifestyle intervention. For this purpose participants 
received a questionnaire with four hypothetical lifestyle interventions. They were 
asked to value the hypothetical scenarios with a grade from “1” to “10” and further-
more they were asked if they would be willing to participate in these hypothetical 
programs. Linear and logistic regression techniques were used for the analyses. 
RESULTS: The factors “group activity,” “counselling,” and “receiving money” were 
positively associated with the scores of the valuation of the programmes. Logistic 
regression analysis showed that money was the only factor that was independently 
associated with respondents’ willingness to participate in a lifestyle intervention. 
Subgroup analysis showed that receiving an amount of money was not associated with 
willingness to participate, but having to pay is negatively associated with participation 
in the lifestyle intervention. CONCLUSIONS: It appeared that only ﬁ nancial disincen-
tives were independently associated with willingness to participate in a lifestyle inter-
vention. Our conjoint analysis results suggest that ﬁ nancial incentives, in the form of 
bonuses, cannot be used to encourage people to participate in lifestyle interventions. 
Financial incentives, in the form of payments might however discourage participation, 
regardless of the content of the program.
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OBJECTIVES: To present HRQL data from a previously presented survey on T2D 
patients’ perceived quality of care in Stockholm, Sweden. METHODS: A postal survey 
including EQ-5D was distributed to 1000 members of the Stockholm Diabetic Patient 
Association and 1000 patients from ﬁ ve primary health care centers. Patients were 
randomly selected, >18 years, having a diabetes diagnosis. Analysis of variance was 
used to test the statistical hypothesis that patients within each subgroup had equal 
mean utility. RESULTS: Response rate was 65% (1319/2000 questionnaires). T2D 
diagnose was reported for 961 respondents of which 858 completed the EQ-5D 
questionnaire. Mean age 69 years, 48.5 % female, BMI 28.4 kg/m2, mean duration 
of T2D 11.3 years. Overall, the mean (SD) utility was 0.765 (0.260) and the current 
health status reported on the VAS scale was 0.727 (0.189). Patients without any 
hypoglycemic episode the previous month had a utility of 0.799 while those with 1, 
2–5 or >5 episodes reported 0.774, 0.687 and 0.633, respectively. More than one 
hypoglycemic episode resulted in signiﬁ cantly lower utility compared to none or only 
one episode (P < 0.0001). The utility of obese patients, 0.704, was signiﬁ cantly lower 
than for patients of normal weight, 0.806, or overweight, 0.790 (P < 0.0001). The 
utility of patients not considering themselves responsible for the management of their 
T2D was signiﬁ cantly lower, 0.608, compared to patients taking a limited, 0.774, or 
full, 0.759, responsibility (P = 0.0005). Patients considering themselves having insuf-
ﬁ cient knowledge to cope with their T2D reported a lower utility, 0.689, compared 
to patients with sufﬁ cient knowledge, 0.789 (P < 0.0001). Male respondents had a 
higher utility, 0.796, compared to females, 0.731 (P = 0.0002). CONCLUSIONS: 
Experience of hypoglycemic episodes, obesity, gender, patients’ perception of personal 
responsibility and perceived knowledge about type 2 diabetes has signiﬁ cant impact 
on health related quality of life in patients with type 2 diabetes.
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OBJECTIVES: Cost-utility analysis in diabetes requires utility estimates for diabetic 
complications. Models frequently rely on UKPDS data. UK requirements for prefer-
ence elicitation have changed since UKPDS publication. We conducted a systematic 
review of the literature to identify utility values for diabetes complications suitable for 
use in Health Technology Assessment (HTA). METHODS: A systematic search of 
online databases was conducted using key words relating to diabetes, major complica-
tions, utility assessment and quality of life. Reference lists of identiﬁ ed citations were 
reviewed. Studies reporting utility single-index measures in patients with any of 33 
pre-speciﬁ ed diabetes related states were included: states considered were diabetic 
complications and adverse events associated with anti-diabetic therapies (AEs). Papers 
were qualitatively assessed: criteria included relevance of studied population to Type 
1 or Type 2 diabetes, sample size, methodological quality and consistency with current 
UK HTA guidelines. Comorbidity is common in diabetes: methodology papers 
addressing combination of utility values were identiﬁ ed in a structured search and 
reviewed. RESULTS: The search returned 3024 hits, 169 articles were reviewed and 
32 publications were identiﬁ ed as suitable for review. Utility or disutility values suit-
able for UK HTA were obtained for 23 diabetes states. For 10 complications, including 
late stage renal disease and some AEs, no utility value were identiﬁ ed that met UK 
HTA criteria. There is no consensus in the literature on how utility measures should 
be combined in patients with more than one complication. CONCLUSIONS: We 
identiﬁ ed a set of utility values suitable for economic analysis for HTA in diabetes. 
To further inform UK HTA, additional research should create robust utility values for 
diabetic renal disease, and evaluate the empirical accuracy of alternative methods of 
combining utility values in patients with multiple complications.
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OBJECTIVES: The study is to measure the health-related quality of life (HRQOL) in 
type 2 diabetes mellitus (T2DM) patients with oral anti-diabetic drugs (OADs) therapy 
using the Chinese version of EQ-5D, and examine their health status. METHODS: 
The study was a cross-sectional survey conducted at 75 hospitals in nine cities in 
China. There were 9577 T2DM patients administered with OADs therapy completed 
the questionnaires. The survey period was from December 3rd, 2008 to July 31st, 2009. 
Patients evaluated their health status using ﬁ ve dimensions (5D) and a visual analog 
scale (VAS). Descriptive statistics was used to describe patients’ demographic charac-
teristics, duration of the disease, the frequency of 5D responses and VAS score. STATA 
9.2 was used for the analyses. RESULTS: The mean age of patients (±SD) was 59.5 
± 12.7 years. 51.1% were male. The mean body mass index (±SD) was 24.3 ± 3.4 kg/
m2. The mean duration of disease (±SD) was 7.9 ± 6.3 years. For the ﬁ ve dimensions 
